#Exosomes, key players in intercellular communication, present unique challenges in research due to their involvement in various physiological processes. MIVO's multi-organ framework offers a breakthrough in decoding exosomal communication. By connecting different organs and replicating physiological conditions, #MIVO provides a platform to study the intricate roles of exosomes in systemic health and disease. This capability holds promise for uncovering new biomarkers and therapeutic targets associated with exosome-mediated processes.
Chi siamo
React4Life is an Italian biotech company transforming the preclinical research landscape by successfully addressing challenges for hundreds of clients worldwide. At the heart of React4Life lies our revolutionary MIVO® technology, backed by over two decades of dedicated academic research. We are pioneers in the development of MIVO®-based organ-on-chip systems, representing a breakthrough in microphysiological technology for faithfully recapitulating human biology in the lab. MIVO® human on chip platform overcomes the limits of traditional in vitro assays and animal models. It improves the reliability and predictivity of several applications in the fields of drug testing, personalized medicine, immuno-oncology, dermocosmetics, and nutraceuticals. At React4life, Italian creativity transforms biotech challenges into customized, cutting-edge solutions. Our worldwide clients' feedback fuels our commitment to meeting their evolving needs. Learn more at www.react4life.com
- Sito Web
-
https://www.react4life.com
Link esterno per React4life
- Settore
- Ricerca biotecnologica
- Dimensioni dell’azienda
- 2-10 dipendenti
- Sede principale
- Genova, Liguria
- Tipo
- Società privata non quotata
- Data di fondazione
- 2016
- Settori di competenza
- R&D, Biotechnology, Life Science, Bioreactors, Cell culture, Toxicity tests, Digestibility tests, In vitro tests, Permeability tests, organ-on-chip e microphysiological systems
Località
-
Principale
Via Greto di Cornigliano, 6r
Genova, Liguria 16152, IT
Dipendenti presso React4life
-
Maurizio Aiello
CEO React4life S.p.A., Senior Technologist CNR, MBA candidate
-
Luca A. Baroldi Torelli, M.D.
Board Member X TE! Innovative Healthcare Services. Shareholder & Mentor presso React4life. Shareholder Hemera Pharma.
-
Natalia Ozimo
LifeScience | Biotech | Organ-on-chip
-
Silvia Scaglione
Chief Research Officer React4life, CNR researcher, Project Coordinator B2B FET-OPEN
Aggiornamenti
-
Advancing Cancer Immunotherapies with organ on chip models. Chernyavska’s review provides an overview of the current and potential applications of advanced in vitro tumor models in cancer immunotherapy development. Within this landscape, the #MIVO platform stands out as a powerful tool for recreating physiological conditions. In this environment, NK cells can migrate against gravity while circulating in the fluid flow. It's been possible to observe the preferential recruitment of CD16-negative NK cells to neuroblastoma spheroids, as well as NK cell-mediated tumor cell death. This millifluidic model is invaluable for studying NK cell behavior, migration, and anticancer therapy efficacy, paving the way for innovative clinical applications and breakthroughs in cancer treatment. Check the review 👉 https://lnkd.in/dCXMG8Ct Learn more about our model 👉 https://lnkd.in/dx9HBh_w #CancerResearch #Immunotherapy #NKCells #Oncology
-
-
Curious about studying the gut-skin axis and the effects of microbiota dysbiosis on skin disorders? Meet our senior scientist, Elisabetta Palamà, at the Controlled Release Society (CRS) 2024 Annual Meeting, in Bologna. Discover our innovative multi-organ-on-chip platform, let's schedule a meeting! #dysbiosis #GutOnChip #GutSkinAxis
-
-
Great article on our latest news and milestones! Thanks Crowdfunding Buzz for sharing it!
React4life, scaleup biotech italiana che aveva raccolto 600 mila euro su CrowdFundMe, raddoppia il fatturato e ottiene un riconoscimento internazionale dalla Commissione UE Stefania Peveraro Francesca Vercesi Tommaso Baldissera Pacchetti Silvia Scaglione Maurizio Aiello Luca Sellari Franceschini Giancarlo Vergine
-
Today is the last day at #Euroocs2024, and we want to make the most of it with you! Don’t miss the chance to visit us at booth 7 to learn more about our brand-new Tokyo Platform. Also, come and check out our poster F-017 today from 12:30 to 18:00. We would love to share our research and developments with you! See you there!
-
-
Latest update from #Euroocs2024! 🌟 Our Chief Scientist, Silvia Scaglione, just shared insights on our organ-on-chip approach to advance drug testing and human disease modeling. Utilizing 3D cancer tissues and immune cells in dynamic circulation, #MIVO enhances reliability and predictive results. Stay tuned for more updates and insights from the conference!
-
-
📣 Introducing TOKYO – Our Latest Innovation in Millifluidics! 🚀 We're excited to unveil TOKYO, our newest breakthrough millifluidic platform! Come and learn more about TOKYO during #EUROoCS2024 in Milan. Our team is ready to showcase its unparalleled reliability and to answer all your questions. We can’t wait to share this groundbreaking advancement with you! See you at booth 7! Find out more 👉 https://lnkd.in/dTWYHixp #Tokyo #Millifluidic #MIVO #ScientificResearch #Euroocs2024
-
🌟 Visit Us at EuroOCS 2024! 🌟 Come visit us at #EuroOCS2024! Discover the exciting new innovation that we're announcing today, right here in Milan! Our team is eager to share all the details and answer any questions. Don't miss out on this groundbreaking advancement in the biomedical field. See you at booth 7! #EuroOCS2024 #Innovation #ScientificResearch #Millifluidic #TOKYOPlatform
-
-
🌍 Let's move closer to the present day in our journey through the history of scientific discovery! Ep. 8 - Recent Innovations in Millifluidics 🔬 In the 2020s, innovations in millifluidics have significantly advanced scientific and medical research, introducing cutting-edge platforms for drug testing, cellular studies, and translational research. While microfluidics excel in diagnostic applications, millifluidics shine when there's a need to circulate cells, grow three-dimensional tissues, and recreate complex human physiological environments. By providing clinically relevant dimensions and fluid flow that mimics circulation in the human body, millifluidic technologies significantly enhance the predictivity and accuracy of assays, paving the way to personalized medicine. What awaits us in 2024? Stay tuned to find out more at Euroocs 2024! 🚀 #Tokyo #Millifluidic #MIVO #ScientificResearch #Euroocs2024
-
🌍 Another step into our journey through the history of scientific discovery! Ep. 7 - Development of Microfluidics 🔬 In the 1990s, the development of microfluidics enabled precise control of minute fluid volumes, revolutionizing diagnostic tools. This advancement led to the creation of lab-on-a-chip technologies, allowing for testing with minimal sample sizes and paving the way for portable diagnostic devices. What awaits us in 2024? 🚀 Stay tuned to find out more at Euroocs 2024! 🚀 #Tokyo #Millifluidic #MIVO #ScientificResearch #Euroocs2024
Pagine simili
Sfoglia le offerte di lavoro
Raccolta fondi
Ultimo round
Finanziamento del debito